MEDIVIR
Medivir AB, commonly referred to as Medivir, is a Swedish biopharmaceutical company headquartered in Stockholm, Sweden. Founded in 1988, Medivir has established itself in the biotechnology industry, focusing primarily on the development of innovative antiviral therapies. The company is renowned for its expertise in drug discovery and development, particularly in the fields of oncology and infectious diseases. Medivir's core products include a range of proprietary antiviral treatments, with a notable emphasis on therapies targeting hepatitis C and other viral infections. The company has achieved significant milestones, including partnerships with leading pharmaceutical firms, which have bolstered its market position. With a commitment to advancing healthcare solutions, Medivir continues to make strides in the biopharmaceutical landscape, contributing to improved patient outcomes globally.
DitchCarbon Score
How does MEDIVIR's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
MEDIVIR's score of 6 is higher than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
MEDIVIR's reported carbon emissions
MEDIVIR, headquartered in Sweden (SE), currently does not have available data on its carbon emissions, as no specific emissions figures have been provided. Consequently, there are no reported Scope 1, 2, or 3 emissions data to analyse. In the absence of concrete emissions data, it is important to note that MEDIVIR has not outlined any specific reduction targets or climate commitments. This lack of information suggests that the company may still be in the early stages of developing a comprehensive climate strategy or reporting framework. As the pharmaceutical industry increasingly prioritises sustainability, MEDIVIR's future climate initiatives will be crucial in aligning with industry standards and expectations. The company may benefit from establishing clear emissions reduction targets and engaging in climate pledges to enhance its environmental responsibility and transparency.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
MEDIVIR is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
